As of 2024-12-15, the EV/EBITDA ratio of Xlife Sciences AG (XLS.SW) is -77.58. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. XLS.SW's latest enterprise value is 204.59 mil CHF. XLS.SW's TTM EBITDA according to its financial statements is -2.64 mil CHF. Dividing these 2 quantities gives us the above XLS.SW EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 17.7x - 23.9x | 19.1x |
| Forward P/E multiples | 17.6x - 18.1x | 17.6x |
| Fair Price | (17.76) - (17.95) | (18.07) |
| Upside | -168.3% - -169.0% | -169.5% |
| Date | EV/EBITDA |
| 2024-12-13 | -77.58 |
| 2024-12-12 | -77.58 |
| 2024-12-11 | -77.15 |
| 2024-12-10 | -82.15 |
| 2024-12-09 | -78.89 |
| 2024-12-06 | -79.54 |
| 2024-12-05 | -77.58 |
| 2024-12-04 | -83.89 |
| 2024-12-03 | -78.23 |
| 2024-12-02 | -78.02 |
| 2024-11-29 | -81.28 |
| 2024-11-28 | -80.19 |
| 2024-11-27 | -83.24 |
| 2024-11-26 | -82.15 |
| 2024-11-25 | -84.55 |
| 2024-11-22 | -84.33 |
| 2024-11-21 | -83.89 |
| 2024-11-20 | -79.11 |
| 2024-11-19 | -77.58 |
| 2024-11-18 | -77.58 |
| 2024-11-15 | -83.24 |
| 2024-11-14 | -81.93 |
| 2024-11-13 | -82.37 |
| 2024-11-12 | -83.24 |
| 2024-11-11 | -79.32 |
| 2024-11-08 | -73.23 |
| 2024-11-07 | -71.70 |
| 2024-11-06 | -73.66 |
| 2024-11-05 | -73.66 |
| 2024-11-04 | -73.66 |
| 2024-11-01 | -73.01 |
| 2024-10-31 | -75.19 |
| 2024-10-30 | -74.32 |
| 2024-10-29 | -74.97 |
| 2024-10-28 | -75.62 |
| 2024-10-25 | -76.93 |
| 2024-10-24 | -76.28 |
| 2024-10-23 | -75.62 |
| 2024-10-22 | -76.71 |
| 2024-10-21 | -77.80 |
| 2024-10-18 | -80.63 |
| 2024-10-17 | -80.85 |
| 2024-10-16 | -80.85 |
| 2024-10-15 | -78.67 |
| 2024-10-14 | -77.58 |
| 2024-10-11 | -75.40 |
| 2024-10-10 | -75.40 |
| 2024-10-09 | -75.62 |
| 2024-10-08 | -79.11 |
| 2024-10-07 | -79.76 |